education
Download App
Indonesia
search
Masuk
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Country
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
search
UserName
Profession
Email
Account
Manage Account
Change Password
Sign Out
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Other Services
Education
Download App
Country
Indonesia
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
Account
Masuk
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Iklan
Iklan
MIMS home
Drugs
Info
Femisic
Femisic
mefenamic acid
Manufacturer:
Caprifarmindo
SELECT
Concise Prescribing Info
Bahasa Concise Prescribing Info
Concise Prescribing Info
Bahasa Concise Prescribing Info
Concise Prescribing Info
Contents
Mefenamic acid
Indications/Uses
Relief of mild to moderate pain eg, headache, toothache, dysmenorrhea, traumatic pain, painful musculoskeletal conditions & post-op.
Dosage/Direction for Use
Adult & childn >14 yr
Initially 500 mg followed by 250 mg 6 hrly.
Administration
Should be taken with food: Take immediately after meals.
Contraindications
Bronchospasm, allergic rhinitis & urticaria after acetosal/aspirin intake; peptic & intestinal ulcer; renal impairment.
Special Precautions
Pregnancy & lactation. Childn <14 yr.
Adverse Reactions
Nausea, vomiting, diarrhea, abdominal pain; leucopenia, eosinophilia, thrombocytopenia, agranulocytopenia; somnolence, dizziness, blurred vision, insomnia.
View
ADR Reporting Link
Drug Interactions
Oral anticoagulants.
MIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
ATC Classification
M01AG01 - mefenamic acid ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, fenamates.
Regulatory Classification
K
Presentation/Packing
Form
Femisic FC caplet 500 mg
Packing/Price
10 × 10's (Rp145,000/boks)
Iklan
Iklan
Iklan
Iklan
Iklan
Iklan
Iklan
Daftar Gratis untuk melanjutkan membaca
Lanjutkan dengan Google
Daftar dengan email
Sudah punya akun?
Masuk